176 related articles for article (PubMed ID: 32196719)
21. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
[TBL] [Abstract][Full Text] [Related]
22. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
23. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
[TBL] [Abstract][Full Text] [Related]
24. Associations between age, cytogenetics, FLT3-ITD, and marrow leukemia cells identified by flow cytometry.
Su L; Gao SJ; Tan YH; Han W; Li W
Asian Pac J Cancer Prev; 2013; 14(9):5341-4. PubMed ID: 24175822
[TBL] [Abstract][Full Text] [Related]
25. Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia.
Tong WG; Sandhu VK; Wood BL; Hendrie PC; Becker PS; Pagel JM; Walter RB; Estey EH
Haematologica; 2015 Mar; 100(3):e97-8. PubMed ID: 25527567
[No Abstract] [Full Text] [Related]
26. Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA.
Kansal R
Hum Pathol; 2019 Aug; 90():80-96. PubMed ID: 31077683
[TBL] [Abstract][Full Text] [Related]
27. How I diagnose and treat NPM1-mutated AML.
Falini B; Brunetti L; Martelli MP
Blood; 2021 Feb; 137(5):589-599. PubMed ID: 33171486
[TBL] [Abstract][Full Text] [Related]
28. Post-bone-marrow-transplant leukemia cutis.
Pulgar F; Vélez D; Valdeolivas N; García J; Cabrera A; Pericet L; Trasobares L; Medina S; García M
Dermatol Online J; 2013 Feb; 19(2):6. PubMed ID: 23473276
[TBL] [Abstract][Full Text] [Related]
29. Disseminated De Novo Myeloid Sarcoma in a 17-year-old Boy.
Sandre MK; Liu A; Levy R
Pediatr Dermatol; 2019 Jul; 36(4):509-510. PubMed ID: 30941787
[TBL] [Abstract][Full Text] [Related]
30. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
[TBL] [Abstract][Full Text] [Related]
31. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
32. Connecting the Dots: A Case of Myeloid Sarcoma.
Rose A; Brayer J
Am J Med; 2018 Sep; 131(9):e357-e359. PubMed ID: 29729239
[No Abstract] [Full Text] [Related]
33. Getting away with phase transition: NPM1-mutated bone myeloid sarcoma mimicking Ewing sarcoma.
Marra A; Martino G; Ascani S; Martelli MP; Falini B
Ann Hematol; 2019 Aug; 98(8):2017-2018. PubMed ID: 30879096
[No Abstract] [Full Text] [Related]
34. Asymptomatic Green-Gray Nodules on the Chest.
Amigo MA; Kaffenberger BH; Chung CG
JAMA Dermatol; 2020 Sep; 156(9):1014-1015. PubMed ID: 32459311
[No Abstract] [Full Text] [Related]
35. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
Rubio P; Campos B; Digiorge JA; Gallego MS; Medina A; Rossi JG; Felice MS; Alonso CN
Int J Hematol; 2016 Nov; 104(5):582-590. PubMed ID: 27436336
[TBL] [Abstract][Full Text] [Related]
36. [Correlation of NPM1, FLT3-ITD mutations with leukocyte count and myeloblasts percentage in AML patients with normal karyotype].
Su L; Li W; Cui JW; Tan YH; Yang Y; Liu XL; Yu P; Hu RP; Wang LL; Gao SJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):571-5. PubMed ID: 23815900
[TBL] [Abstract][Full Text] [Related]
37. Leukemia cutis from CD56 positive, myeloperoxidase negative acute myeloid leukemia.
Abdou AG; Seleit I; Bakry OA; Abdel-Wahed MM
Acta Dermatovenerol Croat; 2013; 21(3):189-92. PubMed ID: 24183224
[TBL] [Abstract][Full Text] [Related]
38. Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations.
Marceau-Renaut A; Guihard S; Castaigne S; Dombret H; Preudhomme C; Cheok M
Am J Hematol; 2015 May; 90(5):E93-4. PubMed ID: 25611491
[No Abstract] [Full Text] [Related]
39. NPM1, FLT3-ITD, CEBPA, and c-kit mutations in 312 Chinese patients with de novo acute myeloid leukemia.
Su L; Gao SJ; Li W; Tan YH; Cui JW; Hu RP
Hematology; 2014 Sep; 19(6):324-8. PubMed ID: 24164801
[TBL] [Abstract][Full Text] [Related]
40. Bone Marrow Clonogenic Myeloid Progenitors from
Guardia RD; González-Silva L; López-Millán B; Rodríguez-Sevilla JJ; Baroni ML; Bueno C; Anguita E; Vives S; Palomo L; Lapillonne H; Varela I; Menendez P
Genes (Basel); 2020 Jan; 11(1):. PubMed ID: 31936647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
